Last reviewed · How we verify
Vivotif Typhoid Oral Vaccine
Vivotif is a live attenuated oral typhoid vaccine that stimulates immune responses against Salmonella typhi through mucosal and systemic immunity.
Vivotif is a live attenuated oral typhoid vaccine that stimulates immune responses against Salmonella typhi through mucosal and systemic immunity. Used for Prevention of typhoid fever caused by Salmonella typhi in travelers and at-risk populations.
At a glance
| Generic name | Vivotif Typhoid Oral Vaccine |
|---|---|
| Also known as | Ty21a Typhoid Oral Vaccine |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Live attenuated vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a live, weakened strain of Salmonella typhi (Ty21a) that replicates in the intestinal tract, triggering both local mucosal immunity (IgA antibodies) and systemic immune responses (IgG antibodies and T-cell responses). This dual immune activation provides protection against infection with wild-type typhoid bacteria.
Approved indications
- Prevention of typhoid fever caused by Salmonella typhi in travelers and at-risk populations
Common side effects
- Abdominal pain or cramping
- Nausea
- Diarrhea
- Vomiting
- Fever
- Headache
Key clinical trials
- Blood Donor CVD 5000 (PHASE4)
- CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults (PHASE4)
- Induction of Gut Permeability by an Oral Vaccine (EARLY_PHASE1)
- CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera (PHASE4)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (PHASE4)
- Understanding Typhoid Disease After Vaccination (PHASE2)
- Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vivotif Typhoid Oral Vaccine CI brief — competitive landscape report
- Vivotif Typhoid Oral Vaccine updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI